VPAC2 receptor agonist BAY 55-9837 increases SMN protein levels and moderates disease phenotype in severe spinal muscular atrophy mouse models

Orphanet Journal of Rare Diseases

Volumn 9, Issue 1, 2014, Pages

  Hadwen, Jeremiah ^a,b   Mackenzie, Duncan ^b   Shamim, Fahad ^b   Mongeon, Kevin ^a,b   Holcik, Martin ^a,b   Mackenzie, Alex ^a,b   Farooq, Faraz ^b  

^a UNIVERSITY OF OTTAWA   (Canada)

^b CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

Author keywords

p38 pathway; SMA; SMN; Therapeutics; VPAC2 receptor agonist

Indexed keywords

BAY 55 9837; G PROTEIN COUPLED RECEPTOR; HORMONE RECEPTOR STIMULATING AGENT; MITOGEN ACTIVATED PROTEIN KINASE P38; SURVIVAL MOTOR NEURON PROTEIN; SURVIVAL MOTOR NEURON PROTEIN 2; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD-1 MOUSE; CELL CULTURE; COMPARATIVE STUDY; GENE EXPRESSION; GENOTYPE; HUMAN; MOTOR PERFORMANCE; MOUSE; NONHUMAN; PHENOTYPE; PROTEIN DETERMINATION; SPINAL MUSCULAR ATROPHY; WESTERN BLOTTING;

ANIMALS; DISEASE MODELS, ANIMAL; MICE; MUSCULAR ATROPHY, SPINAL; PEPTIDE FRAGMENTS; RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE, TYPE II; SURVIVAL OF MOTOR NEURON 1 PROTEIN; VASOACTIVE INTESTINAL PEPTIDE;

EID: 84892150517     PISSN: None     EISSN: 17501172     Source Type: Journal    
DOI: 10.1186/1750-1172-9-4     Document Type: Article

References (39)

1. Pan-ethnic carrier screening and prenatal diagnosis for spinal muscular atrophy: clinical laboratory analysis of >72,400 specimens. Sugarman EA, Nagan N, Zhu H, Akmaev VR, Zhou Z, Rohlfs EM, Flynn K, Hendrickson BC, Scholl T, Sirko-Osadsa DA, Allitto BA, Eur J Hum Gen 2012 20 27 32 10.1038/ejhg.2011.134
2. Spinal muscular atrophy. D'Amico A, Mercuri E, Tiziano FD, Bertini E, Orphanet J Rare Dis 2011 6 71 10.1186/1750-1172-6-71 22047105
3. Identification and characterization of a spinal muscular atrophy-determining gene. Lefebvre S, Burglen L, Reboullet S, Clermont O, Burlet P, Viollet L, Benichou B, Cruaud C, Millasseau P, Zeviani M, Cell 1995 80 155 165 10.1016/0092-8674(95)90460-3 7813012
4. A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Lorson CL, Hahnen E, Androphy EJ, Wirth B, Proc Natl Acad Sci USA 1999 96 6307 6311 10.1073/pnas.96.11.6307 10339583 (Pubitemid 29256661)
5. A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2. Monani UR, Lorson CL, Parsons DW, Prior TW, Androphy EJ, Burghes AH, McPherson JD, Hum Mol Genet 1999 8 1177 1183 10.1093/hmg/8.7.1177 10369862 (Pubitemid 29328985)
6. p38 Mitogen-activated protein kinase stabilizes SMN mRNA through RNA binding protein HuR. Farooq F, Balabanian S, Liu X, Holcik M, MacKenzie A, Hum Mol Genet 2009 18 4035 4045 10.1093/hmg/ddp352 19648294
7. Celecoxib increases SMN and survival in a severe spinal muscular atrophy mouse model via p38 pathway activation. Farooq F, Abadia-Molina F, MacKenzie D, Hadwen J, Shamim F, O'Reilly S, Holcik M, MacKenzie A, Hum Mol Genet 2013 22 3415 3424 10.1093/hmg/ddt191 23656793
8. Activation of p38 and p42/44 MAP kinase in neuropathic pain: involvement of VPAC2 and NK2 receptors and mediation by spinal glia. Garry EM, Delaney A, Blackburn-Munro G, Dickinson T, Moss A, Nakalembe I, Robertson DC, Rosie R, Robberecht P, Mitchell R, Fleetwood-Walker SM, Mol Cell Neurosci 2005 30 523 537 10.1016/j.mcn.2005.08.016 16202621 (Pubitemid 41721170)
9. PACAP-38 induces neuronal differentiation of human SH-SY5Y neuroblastoma cells via cAMP-mediated activation of ERK and p38 MAP kinases. Monaghan TK, Mackenzie CJ, Plevin R, Lutz EM, J Neurochem 2008 104 74 88 17995938 (Pubitemid 350265065)
10. Trichostatin A increases SMN expression and survival in a mouse model of spinal muscular atrophy. Avila AM, Burnett BG, Taye AA, Gabanella F, Knight MA, Hartenstein P, Cizman Z, Di Prospero NA, Pellizzoni L, Fischbeck KH, Sumner CJ, J Clin Invest 2007 117 659 671 10.1172/JCI29562 17318264 (Pubitemid 46348524)
11. SAHA ameliorates the SMA phenotype in two mouse models for spinal muscular atrophy. Riessland M, Ackermann B, Forster A, Jakubik M, Hauke J, Garbes L, Fritzsche I, Mende Y, Blumcke I, Hahnen E, Wirth B, Hum Mol Genet 2010 19 1492 1506 10.1093/hmg/ddq023 20097677
12. Regulation of tumour necrosis factor alpha mRNA stability by the mitogen-activated protein kinase p38 signalling cascade. Brook M, Sully G, Clark AR, Saklatvala J, FEBS Lett 2000 483 57 61 10.1016/S0014-5793(00)02084-6 11033356
13. p38 mitogen-activated protein kinase regulates cyclooxygenase-2 mRNA stability and transcription in lipopolysaccharide-treated human monocytes. Dean JL, Brook M, Clark AR, Saklatvala J, J Biol Chem 1999 274 264 269 10.1074/jbc.274.1.264 9867839 (Pubitemid 29035058)
14. p38 Mitogen-activated protein kinase-dependent and -independent signaling of mRNA stability of AU-rich element-containing transcripts. Frevel MA, Bakheet T, Silva AM, Hissong JG, Khabar KS, Williams BR, Mol Cell Biol 2003 23 425 436 10.1128/MCB.23.2.425-436.2003 12509443 (Pubitemid 36050538)
15. Combinations of ERK and p38 MAPK inhibitors ablate tumor necrosis factor-alpha (TNF-alpha) mRNA induction. Evidence for selective destabilization of TNF-alpha transcripts. Rutault K, Hazzalin CA, Mahadevan LC, J Biol Chem 2001 276 6666 6674 10.1074/jbc.M005486200 11076936
16. Cytokine mRNA decay is accelerated by an inhibitor of p38-mitogen-activated protein kinase. Wang SW, Pawlowski J, Wathen ST, Kinney SD, Lichenstein HS, Manthey CL, Inflamm Res 1999 48 533 538 10.1007/ s000110050499 10563470 (Pubitemid 29495635)
17. SB 239063, a novel p38 inhibitor, attenuates early neuronal injury following ischemia. Legos JJ, Erhardt JA, White RF, Lenhard SC, Chandra S, Parsons AA, Tuma RF, Barone FC, Brain Res 2001 892 70 77 10.1016/S0006-8993(00) 03228-5 11172750 (Pubitemid 32126568)
18. SMNDelta7, the major product of the centromeric survival motor neuron (SMN2) gene, extends survival in mice with spinal muscular atrophy and associates with full-length SMN. Le TT, Pham LT, Butchbach ME, Zhang HL, Monani UR, Coovert DD, Gavrilina TO, Xing L, Bassell GJ, Burghes AH, Hum Mol Genet 2005 14 845 857 10.1093/hmg/ddi078 15703193 (Pubitemid 40403280)
19. Localization and characterization of pituitary adenylate cyclase-activating polypeptide receptors in the human cerebellum during development. Basille M, Cartier D, Vaudry D, Lihrmann I, Fournier A, Freger P, Gallo-Payet N, Vaudry H, Gonzalez B, J Comp Neurol 2006 496 468 478 10.1002/cne.20934 16572459 (Pubitemid 43805899)
20. Distribution of the VPAC2 receptor in peripheral tissues of the mouse. Harmar AJ, Sheward WJ, Morrison CF, Waser B, Gugger M, Reubi JC, Endocrinology 2004 145 1203 1210 10.1210/en.2003-1058 14617572 (Pubitemid 38281001)
21. Expression of VIP and/or PACAP receptor mRNA in peptide synthesizing cells within the suprachiasmatic nucleus of the rat and in its efferent target sites. Kalamatianos T, Kallo I, Piggins HD, Coen CW, J Comp Neurol 2004 475 19 35 10.1002/cne.20168 15176082 (Pubitemid 38715799)
22. In vitro evaluation of VIP/PACAP receptors in healthy and diseased human tissues. Clinical implications. Reubi JC, Ann N Y Acad Sci 2000 921 1 25 11193811 (Pubitemid 32094523)
23. Vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor subtypes in human tumors and their tissues of origin. Reubi JC, Laderach U, Waser B, Gebbers JO, Robberecht P, Laissue JA, Cancer Res 2000 60 3105 3112 10850463 (Pubitemid 30395841)
24. Immunocytochemical identification of VPAC1, VPAC2, and PAC1 receptors in normal and neoplastic human tissues with subtype-specific antibodies. Schulz S, Rocken C, Mawrin C, Weise W, Hollt V, Schulz S, Clin Cancer Res 2004 10 8235 8242 10.1158/1078-0432.CCR-04-0939 15623599 (Pubitemid 40053383)
25. The origin and function of the pituitary adenylate cyclase-activating polypeptide (PACAP)/glucagon superfamily. Sherwood NM, Krueckl SL, McRory JE, Endocr Rev 2000 21 619 670 11133067 (Pubitemid 32113287)
26. Different atrophy-hypertrophy transcription pathways in muscles affected by severe and mild spinal muscular atrophy. Millino C, Fanin M, Vettori A, Laveder P, Mostacciuolo ML, Angelini C, Lanfranchi G, BMC Med 2009 7 14 10.1186/1741-7015-7-14 19351384
27. Prolactin increases SMN expression and survival in a mouse model of severe spinal muscular atrophy via the STAT5 pathway. Farooq F, Molina FA, Hadwen J, MacKenzie D, Witherspoon L, Osmond M, Holcik M, MacKenzie A, J Clin Invest 2011 121 3042 3050 10.1172/JCI46276 21785216
28. Vascular perfusion abnormalities in infants with spinal muscular atrophy. Araujo A, Araujo M, Swoboda KJ, J Pediatr 2009 155 292 294 10.1016/j.jpeds. 2009.01.071 19619755
29. Early heart failure in the SMNDelta7 model of spinal muscular atrophy and correction by postnatal scAAV9-SMN delivery. Bevan AK, Hutchinson KR, Foust KD, Braun L, McGovern VL, Schmelzer L, Ward JG, Petruska JC, Lucchesi PA, Burghes AH, Kaspar BK, Hum Mol Genet 2010 19 3895 3905 10.1093/hmg/ddq300 20639395
30. Glucose metabolism and pancreatic defects in spinal muscular atrophy. Bowerman M, Swoboda KJ, Michalski JP, Wang GS, Reeks C, Beauvais A, Murphy K, Woulfe J, Screaton RA, Scott FW, Kothary R, Ann Neurol 2012 72 256 268 10.1002/ana.23582 22926856
31. Motor neuron rescue in spinal muscular atrophy mice demonstrates that sensory-motor defects are a consequence, not a cause, of motor neuron dysfunction. Gogliotti RG, Quinlan KA, Barlow CB, Heier CR, Heckman CJ, Didonato CJ, J Neurosci 2012 32 3818 3829 10.1523/JNEUROSCI.5775-11.2012 22423102
32. Arrhythmia and cardiac defects are a feature of spinal muscular atrophy model mice. Heier CR, Satta R, Lutz C, DiDonato CJ, Hum Mol Genet 2010 19 3906 3918 10.1093/hmg/ddq330 20693262
33. Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model. Hua Y, Sahashi K, Rigo F, Hung G, Horev G, Bennett CF, Krainer AR, Nature 2011 478 123 126 10.1038/nature10485 21979052
34. Survival motor neuron protein in motor neurons determines synaptic integrity in spinal muscular atrophy. Martinez TL, Kong L, Wang X, Osborne MA, Crowder ME, Van Meerbeke JP, Xu X, Davis C, Wooley J, Goldhamer DJ, et al. J Neurosci 2012 32 8703 8715 10.1523/JNEUROSCI.0204-12.2012 22723710
35. Digital necroses and vascular thrombosis in severe spinal muscular atrophy. Rudnik-Schoneborn S, Vogelgesang S, Armbrust S, Graul-Neumann L, Fusch C, Zerres K, Muscle Nerve 2010 42 144 147 10.1002/mus.21654 20583119
36. Cardiac defects contribute to the pathology of spinal muscular atrophy models. Shababi M, Habibi J, Yang HT, Vale SM, Sewell WA, Lorson CL, Hum Mol Genet 2010 19 4059 4071 10.1093/hmg/ddq329 20696672
37. Engineering novel VPAC2-selective agonists with improved stability and glucose-lowering activity in vivo. Pan CQ, Li F, Tom I, Wang W, Dumas M, Froland W, Yung SL, Li Y, Roczniak S, Claus TH, et al. J Pharmacol Exp Ther 2007 320 900 906 17110523 (Pubitemid 46147974)
38. A potent and highly selective VPAC2 agonist enhances glucose-induced insulin release and glucose disposal: a potential therapy for type 2 diabetes. Tsutsumi M, Claus TH, Liang Y, Li Y, Yang L, Zhu J, Dela Cruz F, Peng X, Chen H, Yung SL, et al. Diabetes 2002 51 1453 1460 10.2337/diabetes.51.5.1453 11978642 (Pubitemid 34826611)
39. The specific VPAC2 agonist Bay 55-9837 increases neuronal damage and hemorrhagic transformation after stroke in type 2 diabetic rats. Darsalia V, Mansouri S, Wolbert P, Barde S, Sjoholm A, Patrone C, Neuropeptides 2012 47 133 137 22981158